Slashdot videos: Now with more Slashdot!
We've improved Slashdot's video section; now you can view our video interviews, product close-ups and site visits with all the usual Slashdot options to comment, share, etc. No more walled garden! It's a work in progress -- we hope you'll check it out (Learn more about the recent updates).
The Phase III study "Study 801" of the compound under discussion did have an open-label run-in period, *and* was placebo controlled.
I believe the ct.gov link below is the study under consideration. Regardless, the press release mentions the placebo control.
From the last link:
Zohydro ER was studied in over 1,100 people living with chronic pain who participated in the pivotal Phase 3 efficacy study or an open-label Phase 3 long-term safety study. The efficacy study that enrolled over 500 subjects with chronic low back pain met the primary endpoint in demonstrating that treatment with Zohydro ER resulted in significantly improved chronic pain relief compared to placebo.
Cisco does own it. You are wrong.
UHF! Only saw it once, probably 15-20 years ago, and still remember that line...
I can highly recommend Ben's book "Bad Science". I bought a copy for each of my family members for the holidays. It gives a very realistic overview of the current state of medical research, both from the "mainstream" and "alternative" medicine worlds.
Well, I am a statistician, too.
I hesitate to say too much about a poll where I am not privy to its final aims, but it seems quite plausible that the point of this poll was to decide who Americans admire the *most*. It looks like they got a pretty clear answer to that question. It would be very hard (i.e., require so many respondents) to design a poll powered to differentiate between each possible candidate at some alpha level.
So, I don't share your criticism of this poll as much as the summary in this article.